AP2008004442A0 - Inhibitors of AKT activity - Google Patents

Inhibitors of AKT activity

Info

Publication number
AP2008004442A0
AP2008004442A0 AP2008004442A AP2008004442A AP2008004442A0 AP 2008004442 A0 AP2008004442 A0 AP 2008004442A0 AP 2008004442 A AP2008004442 A AP 2008004442A AP 2008004442 A AP2008004442 A AP 2008004442A AP 2008004442 A0 AP2008004442 A0 AP 2008004442A0
Authority
AP
ARIPO
Prior art keywords
inhibitors
akt activity
akt
activity
Prior art date
Application number
AP2008004442A
Other languages
English (en)
Inventor
Igor Safonov
Dirk A Heering
Tammy J Et Al Clark
Original Assignee
Ithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ithkline Beecham Corp filed Critical Ithkline Beecham Corp
Publication of AP2008004442A0 publication Critical patent/AP2008004442A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2008004442A 2005-11-10 2006-11-09 Inhibitors of AKT activity AP2008004442A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73595505P 2005-11-10 2005-11-10
US77228906P 2006-02-10 2006-02-10
US82692806P 2006-09-26 2006-09-26
PCT/US2006/043513 WO2007058850A2 (en) 2005-11-10 2006-11-09 Inhibitors of akt activity

Publications (1)

Publication Number Publication Date
AP2008004442A0 true AP2008004442A0 (en) 2008-04-30

Family

ID=38049129

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004442A AP2008004442A0 (en) 2005-11-10 2006-11-09 Inhibitors of AKT activity

Country Status (16)

Country Link
US (1) US20100056523A1 (es)
EP (1) EP1948188A4 (es)
JP (1) JP2009516653A (es)
KR (1) KR20080067646A (es)
AP (1) AP2008004442A0 (es)
AR (1) AR056786A1 (es)
AU (1) AU2006315805A1 (es)
BR (1) BRPI0618309A2 (es)
CA (1) CA2629429A1 (es)
EA (1) EA200801301A1 (es)
EC (1) ECSP088425A (es)
IL (1) IL190968A0 (es)
MA (1) MA29935B1 (es)
NO (1) NO20082414L (es)
TW (1) TW200736260A (es)
WO (1) WO2007058850A2 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1948185A4 (en) * 2005-11-10 2010-04-21 Glaxosmithkline Llc INHIBITORS OF AKT ACTIVITY
AU2009205956B2 (en) 2008-01-18 2015-07-02 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
ATE547707T1 (de) * 2008-05-16 2012-03-15 Cellzome Ag Verfahren zur identifizierung von mit parp wechselwirkenden molekülen und zur aufreinigung von parp-proteinen
US20110086834A1 (en) * 2008-06-26 2011-04-14 Amgen Inc. Alkynyl alcohols as kinase inhibitors
RU2011123647A (ru) 2008-11-10 2012-12-20 Вертекс Фармасьютикалз Инкорпорейтед Соединения, полезные в качестве ингибиторов atr киназы
SG172248A1 (en) 2008-12-19 2011-07-28 Vertex Pharma Pyrazine derivatives useful as inhibitors of atr kinase
CA2798763A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2011143399A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2569287B1 (en) 2010-05-12 2014-07-09 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2011143419A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2569284B1 (en) 2010-05-12 2015-07-08 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as inhibitors of atr kinase
NZ605627A (en) 2010-06-23 2015-06-26 Vertex Pharma Pyrrolo-pyrazine derivatives useful as inhibitors of atr kinase
EP2596353A4 (en) 2010-07-23 2014-01-15 Harvard College METHOD FOR DETECTING PRENATAL OR PREGNANT DISEASES OR SUFFERING
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
SG10201505724SA (en) * 2010-07-23 2015-09-29 Harvard College Methods of detecting diseases or conditions using phagocytic cells
WO2012123522A1 (en) 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag 6,5-heterocyclic propargylic alcohol compounds and uses therefor
WO2012138938A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2723747A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2012178123A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846686B2 (en) 2011-09-30 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP3878851A1 (en) 2011-09-30 2021-09-15 Vertex Pharmaceuticals Incorporated Process for making compounds useful as inhibitors of atr kinase
CN103957917A (zh) 2011-09-30 2014-07-30 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776419B1 (en) 2011-11-09 2016-05-11 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776420A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
PL2833973T3 (pl) 2012-04-05 2018-02-28 Vertex Pharmaceuticals Incorporated Związki użyteczne jako inhibitory kinazy ATR i ich terapie skojarzone
EP2904406B1 (en) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
WO2014062604A1 (en) 2012-10-16 2014-04-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
BR112015012454B1 (pt) 2012-12-07 2022-07-05 Vertex Pharmaceuticals Incorporated Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos
US10494675B2 (en) 2013-03-09 2019-12-03 Cell Mdx, Llc Methods of detecting cancer
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
EP3013818B1 (en) * 2013-06-26 2021-12-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (s)-enantiomer of mepazine as paracaspase (malt1) inhibitor for treating cancer
AU2014293011A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) * 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
SG11201604519PA (en) 2013-12-06 2016-07-28 Vertex Pharma 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
EP3152212B9 (en) 2014-06-05 2020-05-27 Vertex Pharmaceuticals Inc. Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
WO2015195740A1 (en) 2014-06-17 2015-12-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
US10323045B2 (en) 2014-10-23 2019-06-18 Janssen Pharmaceutica Nv Thienopyrimidine derivatives as NIK inhibitors
MX371150B (es) 2014-10-23 2020-01-20 Janssen Pharmaceutica Nv NUEVOS DERIVADOS DE PIRAZOL EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
KR102500071B1 (ko) 2014-10-23 2023-02-14 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 화합물
KR102523405B1 (ko) 2014-10-23 2023-04-18 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 피라졸로피리미딘 유도체
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
WO2020078865A1 (en) 2018-10-16 2020-04-23 F. Hoffmann-La Roche Ag Use of akt inhibitors in ophthalmology
KR102650496B1 (ko) 2018-10-31 2024-03-26 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제제로서의 치환된 6-아자벤즈이미다졸 화합물
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200523262A (en) * 2003-07-29 2005-07-16 Smithkline Beecham Corp Inhibitors of AKT activity

Also Published As

Publication number Publication date
EP1948188A2 (en) 2008-07-30
ECSP088425A (es) 2008-06-30
WO2007058850A2 (en) 2007-05-24
US20100056523A1 (en) 2010-03-04
KR20080067646A (ko) 2008-07-21
EP1948188A4 (en) 2011-02-16
CA2629429A1 (en) 2007-05-24
JP2009516653A (ja) 2009-04-23
TW200736260A (en) 2007-10-01
AR056786A1 (es) 2007-10-24
EA200801301A1 (ru) 2009-02-27
MA29935B1 (fr) 2008-11-03
WO2007058850A3 (en) 2009-04-30
AU2006315805A1 (en) 2007-05-24
IL190968A0 (en) 2009-02-11
BRPI0618309A2 (pt) 2011-08-23
NO20082414L (no) 2008-08-05

Similar Documents

Publication Publication Date Title
HRP20130429T1 (en) Inhibitors of akt activity
EP1968568A4 (en) HEMMER OF NUTS ACTIVITY
AP2008004442A0 (en) Inhibitors of AKT activity
EP1850843A4 (en) ACTIVITY INHIBITORS OF AKT
EP1871376A4 (en) INHIBITOR OF AKT ACTIVITY
EP1720855A4 (en) HEMMER OF ACT ACTIVITY
EP1784175A4 (en) INHIBITORS OF ACT ACTIVITY
EP1737861A4 (en) INHIBITORS OF AKT ACTIVITY
EP1827436A4 (en) ACTIVITY INHIBITORS AKT
HK1137758A1 (en) Inhibitors of akt activity akt
HK1225722A1 (zh) 激酶活性抑製劑
HK1132676A1 (en) Inhibitors of akt activity akt
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
IL173174A0 (en) Inhibitors of akt activity
EP1620095A4 (en) INHIBITORS OF AKT ACTIVITY
ZA200706345B (en) Amino-pyridines as inhibitors of ß-secretase
EP2114388A4 (en) INHIBITORS OF AKT'S ACTIVITY
GB0509224D0 (en) Inhibitors of intracellular enzymatic activity
EP1824849A4 (en) INHIBITORS OF AKT ACTIVITY
EP2134175A4 (en) HAMMER OF ACT ACTIVITY
EP2120951A4 (en) INHIBITORS OF AKT ACTIVITY
EP2299825A4 (en) HAMMER OF ACT ACTIVITY
EP1948185A4 (en) INHIBITORS OF AKT ACTIVITY
EP2303017A4 (en) HAMMER OF ACT ACTIVITY